FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 463 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR The vaccination of a generation? – That Cancer Conversation December 9, 2021 Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... March 10, 2025 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 Breast Cancer Risk Genes February 10, 2021 Load more HOT NEWS Ending smoking could more than halve England’s cancer inequality gap For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment Blood test could tailor treatment after surgery Opinion: ‘We can’t afford to stop now’
